TY - JOUR
T1 - Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor
AU - Bianchi, Elisabetta
AU - Liang, Xiaoping
AU - Ingallinella, Paolo
AU - Finotto, Marco
AU - Chastain, Michael A.
AU - Fan, Jiang
AU - Fu, Tong Ming
AU - Song, Hong Chang
AU - Horton, Melanie S.
AU - Freed, Daniel C.
AU - Manger, Walter
AU - Wen, Emily
AU - Shi, Li
AU - Ionescu, Roxana
AU - Price, Colleen
AU - Wenger, Marc
AU - Emini, Emilio A.
AU - Cortese, Riccardo
AU - Ciliberto, Gennaro
AU - Shiver, John W.
AU - Pessi, Antonello
PY - 2005/6
Y1 - 2005/6
N2 - Conventional influenza vaccines can prevent infection, but their efficacy depends on the degree of antigenic "match" between the strains used for vaccine preparation and those circulating in the population. A universal influenza vaccine based on invariant regions of the virus, able to provide broadly cross-reactive protection, without requiring continuous manufacturing update, would solve a major medical need. Since the temporal and geographical dominance of the influenza virus type and/or subtype (A/H3, A/H1, or B) cannot yet be predicted, a universal vaccine, like the vaccines currently in use, should include both type A and type B influenza virus components. However, while encouraging preclinical data are available for influenza A virus, no candidate universal vaccine is available for influenza B virus. We show here that a peptide conjugate vaccine, based on the highly conserved maturational cleavage site of the HA0 precursor of the influenza B virus hemagglutinin, can elicit a protective immune response against lethal challenge with viruses belonging to either one of the representative, non-antigenically cross-reactive influenza B virus lineages. We demonstrate that protection by the HA0 vaccine is mediated by antibodies, probably through effector mechanisms, and that a major part of the protective response targets the most conserved region of HA0, the P1 residue of the scissile bond and the fusion peptide domain. In addition, we present preliminary evidence that the approach can be extended to influenza A virus, although the equivalent HA0 conjugate is not as efficacious as for influenza B virus.
AB - Conventional influenza vaccines can prevent infection, but their efficacy depends on the degree of antigenic "match" between the strains used for vaccine preparation and those circulating in the population. A universal influenza vaccine based on invariant regions of the virus, able to provide broadly cross-reactive protection, without requiring continuous manufacturing update, would solve a major medical need. Since the temporal and geographical dominance of the influenza virus type and/or subtype (A/H3, A/H1, or B) cannot yet be predicted, a universal vaccine, like the vaccines currently in use, should include both type A and type B influenza virus components. However, while encouraging preclinical data are available for influenza A virus, no candidate universal vaccine is available for influenza B virus. We show here that a peptide conjugate vaccine, based on the highly conserved maturational cleavage site of the HA0 precursor of the influenza B virus hemagglutinin, can elicit a protective immune response against lethal challenge with viruses belonging to either one of the representative, non-antigenically cross-reactive influenza B virus lineages. We demonstrate that protection by the HA0 vaccine is mediated by antibodies, probably through effector mechanisms, and that a major part of the protective response targets the most conserved region of HA0, the P1 residue of the scissile bond and the fusion peptide domain. In addition, we present preliminary evidence that the approach can be extended to influenza A virus, although the equivalent HA0 conjugate is not as efficacious as for influenza B virus.
UR - http://www.scopus.com/inward/record.url?scp=19944403940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19944403940&partnerID=8YFLogxK
U2 - 10.1128/JVI.79.12.7380-7388.2005
DO - 10.1128/JVI.79.12.7380-7388.2005
M3 - Article
C2 - 15919893
AN - SCOPUS:19944403940
VL - 79
SP - 7380
EP - 7388
JO - Journal of Virology
JF - Journal of Virology
SN - 0022-538X
IS - 12
ER -